BioRestorative Therapies Inc (OQ:BRTX)

Apr 30, 2024 04:15 pm ET
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market...
Apr 30, 2024 07:30 am ET
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
year agreement includes BioRestorative supplying its initial commercial product to Cartessa — — Financial impact from commercial partnership expected to provide flexibility for BioRestorative to become significantly less dependent on the...
Apr 16, 2024 07:45 am ET
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important...
Apr 08, 2024 07:45 am ET
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc. (“Galen”) which, combined...
Apr 03, 2024 04:38 pm ET
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the filing of a registration statement on Form S-1 with the Securities and...
Apr 01, 2024 07:45 am ET
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange...
Mar 11, 2024 04:15 pm ET
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at...
Feb 14, 2024 09:15 am ET
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its lead therapeutic candidate for the treatment of patients with chronic lower back pain caused by degenerative disc disease. According to experts, up to 80% of the population will experience back pain at some poin
Feb 06, 2024 08:05 am ET
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into agreements with certain holders of its existing warrants...
Feb 05, 2024 08:31 am ET
Thinking about buying stock in BioRestorative Therapies, Smart for Life, Jabil, CalAmp, or Rail Vision?
NEW YORK, Feb. 5, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRTX, SMFL, JBL, CAMP, and RVSN.
Feb 05, 2024 07:30 am ET
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the public availability of a poster, presented yesterday at the Orthopaedic...
Feb 01, 2024 07:30 am ET
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that preliminary 26–52 week blinded data from the ongoing Phase 2 clinical...
Dec 12, 2023 09:15 am ET
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of...
Oct 09, 2023 12:10 pm ET
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare...
Sep 18, 2023 09:00 am ET
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and diabetes. The company is focusing on developing BRTX-100, its lead therapeutic candidate for the treatment of patients with chronic lower back pain caused by degenerative disc disease. This technology involves using the patient's own stem cells to regenerate damaged discs in the lower
Sep 12, 2023 09:00 am ET
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a supply agreement with Evolutionary Biologics, a...
Sep 08, 2023 08:30 am ET
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that Northwell Health, New York State's largest health care provider, has...
Aug 30, 2023 09:00 am ET
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
MELVILLE, NY / ACCESSWIRE / August 30, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. Back pain can exist alone without nerve involvement and oftentimes, this is the most painful type of chronic pain. Additionally, spinal discs naturally degenerate with age, and as such, many people experience chronic back pain for no reason other than aging.
Aug 02, 2023 09:00 am ET
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
MELVILLE, NY / ACCESSWIRE / August 2, 2023 / Valuations, competitive landscape and market opportunity are fundamental characteristics in evaluating investment decisions. Insider buying - the "smart money" - can also be an indicator to evaluate the potential performance of a company. BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") insiders are expressing their confidence in the company's future. Dale Broadrick, an insider of the company, has demonstrated this faith by acquiring 1,000 sha
Jul 31, 2023 08:05 am ET
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point. BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") recently held a virtual panel about their stem cell-based therapies and one of the first things that Dr. Jason Lipetz, an expert panelist, shared was t
Jul 21, 2023 07:10 am ET
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem cell-based therapies, has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank. The license enables BioRestorative to process mesenchymal stem cells obtained from autologous donors. BioRestorative is now the first facility in New York State to be licensed to process mesenchymal stem cells for clinical use, setting the company apart from
Jul 11, 2023 08:30 am ET
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into a definitive agreement with several accredited and...
Jul 07, 2023 07:00 am ET
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
MELVILLE, NY / ACCESSWIRE / July 7, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100. The independent review body Data Safety Monitoring Board (DSMB) which is overseeing dose and safety related issues during the course of the trial approved the trial's continuation with no changes to the current version of the protocol.
Jun 27, 2023 07:00 am ET
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the independent Data Safety Monitoring Board (“DSMB”), which is overseeing...
Jun 16, 2023 07:00 am ET
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual...
Jun 15, 2023 07:48 am ET
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
MELVILLE, NY / ACCESSWIRE / June 15, 2023 / Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise.
Jun 12, 2023 07:00 am ET
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that the final subject in its BRTX-100 Phase 2 clinical trial safety cohort...
Jun 01, 2023 09:15 am ET
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being...
May 31, 2023 07:00 am ET
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has received a license from the New York State Department of Health to...
May 15, 2023 07:00 am ET
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark Office has issued a notice of allowance...
May 12, 2023 07:15 am ET
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
MELVILLE, NY / ACCESSWIRE / May 12, 2023 / Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. BADSC therapy is a novel and proprietary form of regenerative medicine that is used to
May 08, 2023 07:00 am ET
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a clinical stage company focused on stem cell-based therapies, today announced that it has signed a clinical trial agreement with Northwell Health, New...
May 04, 2023 07:00 am ET
BioRestorative Therapies, Inc. to participate at the EF Hutton Global Conference May 10-11 in New York City
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Inaugural EF Hutton Global Conference...
Apr 24, 2023 07:00 am ET
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed enrollment for the safety run-in component of its Phase 2...
Mar 13, 2023 07:00 am ET
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into an agreement with the Bruder Consulting & Venture...
Mar 07, 2023 06:30 am ET
BioRestorative Therapies to Participate at the 35th Annual ROTH MKM Conference on March 12 -14, 2023
BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate at the Roth 35th Annual...
Mar 02, 2023 07:30 am ET
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of...
Feb 08, 2023 09:00 am ET
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent...
Jan 17, 2023 09:29 am ET
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event
Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology. The company is currently engaged in a Phase 2 trial in Chronic Lumbar Disc Disease, and advancing other programs with BRTX100 and with Brown Adipose Tissue.
Dec 06, 2022 07:00 am ET
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I...
Dec 05, 2022 07:00 am ET
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by...
Nov 29, 2022 11:20 am ET
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on Dec. 5-6, 2022
via InvestorWire – BioRestorative Therapies, Inc. (Nasdaq: BRTX) today announced that Lance Alstodt, its CEO, will be participating at the RHK Capital Disruptive Growth Conference in New York City. EventRHK Capital Disruptive Growth...
Nov 16, 2022 08:56 am ET
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
BioRestorative Therapies, Inc. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will participate on December 5-6, 2022 at the RHK...
Oct 20, 2022 09:30 am ET
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that its CEO, Lance Alstodt, will be interviewed on Famela and Friends Talk Radio Show...
Sep 28, 2022 07:00 am ET
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7th Annual...
Sep 27, 2022 07:00 am ET
BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be participating in the Roth Inaugural Healthcare...
Sep 07, 2022 07:00 am ET
BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14
BioRestorative Therapies. ("BioRestorative" or the "Company") (Nasdaq: BRTX), a clinical stage company focused on the development of first-in-class cell-based therapies, today announced that it will present on September 14, 2022 at the H.C....
Jun 30, 2022 07:30 am ET
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the first patient has been enrolled in the Company’s Phase 2 clinical trial...
Jun 22, 2022 07:30 am ET
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has reached an agreement with its second clinical site for its Phase 2 clinical...
Jun 13, 2022 07:00 am ET
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced site initiation for its Phase 2 clinical trial targeting chronic lumbar disc disease...
Apr 29, 2022 08:00 am ET
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem cell-based therapies, today announced that it is hosting a Principal Investigators Meeting in...
Apr 18, 2022 08:00 am ET
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has selected 10 of its 15 clinical sites for its Phase 2 clinical trial...
Apr 04, 2022 08:00 am ET
BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has completed testing and certification of its clinical grade cell therapy...
Mar 10, 2022 08:00 am ET
BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson,...
Feb 16, 2022 08:30 am ET
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance...
Feb 07, 2022 09:00 am ET
BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has initiated the site selection process for its active Phase 2 clinical trial...
Feb 07, 2022 07:45 am ET
BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced that Lance Alstodt, BioRestorative’s Chairman and CEO, along with Francisco Silva,...
Feb 02, 2022 08:00 am ET
BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued a notice of allowance for a patent...
Jan 26, 2022 06:00 am ET
BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has been named by Insights Care Magazine as one of the ten most innovative...
Jan 11, 2022 06:00 am ET
BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory...
Jan 06, 2022 06:00 am ET
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at...
Jan 04, 2022 06:00 am ET
BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Technology Transfer (STTR) Phase I grant for...
Dec 22, 2021 07:36 am ET
Thinking about buying stock in BioRestorative Therapies, DBV Technologies, Frontline, Galera Therapeutics, or Can Fite Biopharma?
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRTX, DBVT, FRO, GRTX, and CANF.
Dec 21, 2021 04:01 pm ET
BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced it has entered into a Master Service Agreement with PRC Clinical, a contract...
Dec 21, 2021 06:00 am ET
BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced its Chief Executive Officer, Lance Alstodt, will be featured on the James Hicks...
Dec 20, 2021 06:00 am ET
BioRestorative Therapies, Inc. Releases Year-End Message
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today released the following year-end message. As we reach the end of 2021, we are inspired by...
Dec 02, 2021 06:00 am ET
BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has filed ten patent applications related to its BRTX-100 program for...
Nov 19, 2021 06:00 am ET
BioRestorative Therapies Enters into Letter of Intent with PRC Clinical
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has entered into a letter of intent with PRC Clinical, a CRO specializing...
Nov 10, 2021 06:00 am ET
BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer
BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an...
Nov 09, 2021 02:20 pm ET
BioRestorative Therapies Announces Closing of $23 Million Public Offering
BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of...
Nov 04, 2021 09:21 pm ET
BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market
BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the pricing of the underwritten public offering of 2,300,000 units, each consisting of one share of...
Oct 26, 2021 04:05 pm ET
BioRestorative Therapies Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq
BioRestorative Therapies, Inc. (“BRTX” or the “Company”) (OTC: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced its intention to effect a 1-for-4,000 reverse split of its common stock in preparation for the...
Oct 26, 2021 08:00 am ET
BioRestorative Therapies Announces Nomination of Two New Members to the Board of Directors
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced the nomination of two new independent members to its Board of Directors with industry and...
Sep 23, 2021 09:00 am ET
BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of...
Sep 02, 2021 09:00 am ET
BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australian Patent Office has issued the Company a patent related to its metabolic ThermoStem®...
Aug 31, 2021 09:00 am ET
BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program
Derived Stem Cells MELVILLE, N.Y., Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office...
Aug 19, 2021 06:00 am ET
BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has been named one of the Top 10 Spine Device Companies and featured by MedTech...
Aug 11, 2021 08:30 am ET
BioRestorative Therapies Discusses Upcoming Annual Meeting of Stockholders
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today reminded its stockholders that its annual meeting of stockholders will be held on Tuesday, August...
Aug 09, 2021 11:57 am ET
BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering
BioRestorative Therapies, Inc. (“BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for...
Jun 07, 2021 07:00 am ET
CEO Presenting on the Emerging Growth Conference on June 9. Register here
EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 9th Emerging Growth Conference. The...
Jun 07, 2021 06:00 am ET
BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, is pleased to announce that it is has been invited to present at the online Emerging Growth Conference on...
May 10, 2021 06:00 am ET
BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it is initiating expansion of its Melville, New York based research laboratories to...
May 03, 2021 06:00 am ET
BioRestorative Therapies Announces Compliance with SEC Reporting Requirements and “Stop Sign” Removal
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and,...
Apr 05, 2021 06:27 am ET
BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of Nickolay V. Kukekov to the BioRestorative Board of Directors, effective...
Mar 31, 2021 07:03 am ET
BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem® Program
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office has issued a notice of allowance for a patent application related to the...
Mar 22, 2021 06:00 am ET
BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem® Program
BioRestorative Therapies, Inc. (the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office and several International agencies have issued notices of allowance for...
Mar 18, 2021 04:01 pm ET
BioRestorative Therapies Announces Filing of 2019 Annual Report on Form 10-K
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2019 with...
Jan 05, 2021 08:00 am ET
BioRestorative Therapies Provides End of Year Shareholder Letter
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced the following letter from its Chief Executive Officer, Lance Alstodt, to its shareholders...
Nov 20, 2020 07:00 am ET
BioRestorative Therapies Emerges from Chapter 11 Reorganization
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that its amended joint plan of reorganization has become effective and it has emerged from...
Dec 16, 2019 08:00 am ET
BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today feature coverage in the news outlet, IEEE Pulse, a magazine of the IEEE Engineering in...
Dec 12, 2019 09:45 am ET
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance on its...
Oct 23, 2019 09:45 am ET
BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Australia Patent Office has issued a Certificate of Grant for the Company’s patent application titled...
Sep 16, 2019 08:00 am ET
BioRestorative Therapies Scientific Advisory Board Member and Clinical Director of Regenerative Disc/Spine Program, Dr. Wayne J. Olan, to Receive Prestigious Award
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that a member of the Company’s Scientific Advisory Board and its Clinical Director of Regenerative Disc/Spine...
Sep 13, 2019 08:00 pm ET
BioRestorative Therapies Comments on Recent Promotional Activity
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell - based therapies, is providing comment on recent promotional activity concerning its shares of common stock traded on the OTCQB market.  On...
Sep 11, 2019 08:00 am ET
BioRestorative Therapies Announces New Initiative to Target Polycystic Ovarian Syndrome
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has expanded its “off-the-shelf” brown adipose derived stem cell therapeutic pipeline to target...
Sep 05, 2019 09:45 am ET
BioRestorative Therapies’ Stockholders Approve Institutional Investor Agreement and Exchange Agreements
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that, at a special meeting of stockholders, the Company’s stockholders approved the securities purchase...
Jul 31, 2019 09:45 am ET
BioRestorative Therapies Signs $5.4 Million Financing with Institutional Investor
BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has entered into a securities purchase agreement with Arena Investors LP (“Arena”).   The agreement...
Apr 29, 2019 09:45 am ET
BioRestorative Therapies to Present at the 22nd Annual American Society of Gene and Cell Therapy as to Data on its Platform Technology for the Treatment of Metabolic Disorders
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that Francisco Silva, Vice President of Research and Development, will present at the 2019...
Feb 27, 2019 09:45 am ET
BioRestorative Therapies Announces the Creation of a Disc Advisory Committee
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced the creation of a Disc Advisory Committee (“Committee”) of its Scientific Advisory Board...
Nov 15, 2018 09:45 am ET
BioRestorative Therapies Receives Notice of Allowance for Key Metabolic Patent in the United States
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued BioRestorative a Notice of...
Oct 18, 2018 09:45 am ET
BioRestorative Therapies Announces the Appointment of Lance Alstodt as Executive VP and Chief Strategy Officer
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of Lance Alstodt as Executive Vice President and Chief Strategy Officer. In...
Sep 24, 2018 09:45 am ET
BioRestorative Therapies Announces Metabolic Research Collaboration with University of Pennsylvania
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Company has entered into a one-year material transfer agreement with the...
Aug 15, 2018 10:20 am ET
BioRestorative Therapies Announces Publication of Study Results Validating the Benefits of Using Hypoxic Cultured Cells to Treat Patients with Degenerative Disc Disease
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Journal of Translational Medicine has published the results of the Company’s...
Jul 25, 2018 09:45 am ET
BioRestorative Therapies Appoints Jason M. Lipetz, M.D. to its Scientific Advisory Board
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Jason M. Lipetz, M.D. has been appointed to the Company’s Scientific Advisory Board....
Jun 11, 2018 09:45 am ET
BioRestorative Therapies Reports Positive Findings from Independent Review of its BRTX-100 Program
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today reported the findings from Defined Health, which was engaged by the Company to conduct an independent...
May 07, 2018 09:45 am ET
BioRestorative Therapies Appoints Wayne J. Olan, M.D. as Clinical Director of Regenerative Disc/Spine Program
BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Wayne J. Olan, M.D. has been appointed as Clinical Director of the Company’s...
Jan 22, 2018 11:00 am ET
BioRestorative Therapies Announces the Appointment of Adam D. Bergstein as Sr. VP, Planning and Business Development
MELVILLE, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTC:BRTX), a life sciences company focused on stem cell-based therapies, today announced the appointment of Adam Bergstein as Senior Vice President, Planning and...
Apr 20, 2017 09:45 am ET
BioRestorative Therapies Receives Notice of Acceptance for Key Metabolic Patent in Australia
MELVILLE, N.Y., April 20, 2017 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the Australia Patent Office (APO), a division of IP Australia - an agency of the Department of Industry, has issued a Notice of Acceptance for the Company’s patent application covering methods related to BioRestorative’s metabolic program (ThermoStem® Program). Following the Notice of Acceptance, the Company is required to pay the associated fees and the patent should be issued....
Sep 12, 2016 09:45 am ET
BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease
MELVILLE, N.Y., Sept. 12, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Journal of Translational Medicine has published the results of a long-term safety and feasibility study of the injection of autologous, hypoxic cultured mesenchymal stem cells (MSCs) into patients with chronic lumbar degenerative disc disease related to protruding/bulging discs. The Company is preparing for an Investigational New Drug (IND) submission with the FDA to seek clearance to ...
Jul 13, 2016 10:46 am ET
BioRestorative Therapies Announces Presentation at 3rd Annual Regenerative Medicine Essentials Course
MELVILLE, N.Y., July 13, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Ed Field, the Company’s President of the Disc/Spine Division, is presenting at the 3rd Annual Regenerative Medicine Essentials Course, held by the Wake Forest Institute for Regenerative Medicine in Winston Salem, NC. On Friday, July 15th, Mr. Field will deliver his presentation entitled, "Getting to Market:  Interactive case studies with discussions on clinical trial plans, regulatory pathw...
Jun 28, 2016 09:45 am ET
BioRestorative Therapies Announces Completion of Human Safety and Feasibility Study on the Use of Hypoxic Cultured Stem Cells to Treat Chronic Lower Back Pain
MELVILLE, N.Y., June 28, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced the completion of a human study entitled “Re-consenting and Follow-Up of Adults from a Retrospective Study Using Autologous Transplantation of Marrow Derived Mesenchymal Stem Cells to Degenerated Intervertebral Disc." The study showed that no adverse events related to the intra-discal injection of autologous, hypoxic cultured, bone marrow-derived mesenchymal stem cells (MSCs) occurred at the tim...
May 31, 2016 07:49 pm ET
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
NEW YORK, May 31, 2016 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lineup of OTCQX® Best and OTCQB® Venture Market companies presenting at the Marcum MicroCap Conference, taking place June 1-2nd at the Grand Hyatt New York.  The Marcum MicroCap Conference, is dedicated to providing a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community.  The Conference will feature presentations by CEOs and CFOs from various industr
May 31, 2016 09:45 am ET
BioRestorative Therapies to Present at 5th Annual Marcum MicroCap Conference
MELVILLE, N.Y., May 31, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Mark Weinreb, the Company’s CEO, will present a Company overview at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel.  The Company’s presentation is scheduled to begin between 10:30 AM - 11:00 AM ET....
May 23, 2016 09:45 am ET
BioRestorative Therapies Announces Promising Data to Advance its Program for the Treatment of Metabolic Disorders
MELVILLE, N.Y., May 23, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or "the Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that promising data has been developed on the transplantation of human stem cell-derived tissue engineered brown fat into an encapsulation device to be used as a cell delivery system for the Company’s metabolic platform program for the treatment of type 2 diabetes, obesity, hyperlipidemia and hypertension. This advancement may lead to successful transplantation of brown fat in humans....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.